Vitamin D3 supplementation scheme in HIV-infected patients based upon pharmacokinetic modelling of 25-hydroxycholecalciferol

British Journal of Clinical Pharmacology

Volumn 75, Issue 5, 2013, Pages 1312-1320

  Foissac, Frantz ^a,b   Tréluyer, Jean Marc ^a,b,c   Souberbielle, Jean Claude ^d   Rostane, Hafeda ^e   Urien, Saïk ^a,b   Viard, Jean Paul ^a,e  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c APHP ^*  (France)

^d Section of Radiology   (France)

^e HÔTEL DIEU   (France)

Author keywords

25 hydroxycholecalciferol; HIV infected adults patients; Population pharmacokinetics

Indexed keywords

CALCIFEDIOL; EFAVIRENZ; PROTEINASE INHIBITOR; TENOFOVIR DISOPROXIL; ANTIRETROVIRUS AGENT; BONE DENSITY CONSERVATION AGENT; COLECALCIFEROL; VITAMIN;

ADOLESCENT; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VITAMIN SUPPLEMENTATION; DIET SUPPLEMENTATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MIDDLE AGED; RADIOIMMUNOASSAY; SEASON; SKIN PIGMENTATION; THEORETICAL MODEL; VERY ELDERLY; VITAMIN D DEFICIENCY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-RETROVIRAL AGENTS; BONE DENSITY CONSERVATION AGENTS; CALCIFEDIOL; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; SEASONS; SKIN PIGMENTATION; VITAMIN D DEFICIENCY; VITAMINS; YOUNG ADULT;

EID: 84876018070     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12006     Document Type: Article

References (46)

1. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
2. Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF, Heaney RP, Holick MF, Hollis BW, Lamberg-Allardt C, McGrath JJ, Norman AW, Scragg R, Whiting SJ, Willett WC, Zittermann A. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr 2007; 85: 649-650.
3. Souberbielle J-C, Body J-J, Lappe JM, Plebani M, Shoenfeld Y, Wang TJ, Bischoff-Ferrari HA, Cavalier E, Ebeling PR, Fardellone P, Gandini S, Gruson D, Guérin AP, Heickendorff L, Hollis BW, Ish-Shalom S, Jean G, von Landenberg P, Largura A, Olsson T, Pierrot-Deseilligny C, Pilz S, Tincani A, Valcour A, Zittermann A. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev 2010; 9: 709-715.
4. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16: 713-716.
5. Thacher TD, Clarke BL. Vitamin D insufficiency. Mayo Clin Proc 2011; 86: 50-60.
6. Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med 2011; 364: 248-254.
7. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009; 19: 73-78.
8. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008; 88: 582S-586.
9. Shinchuk L, Holick MF. Vitamin D and rehabilitation: improving functional outcomes. Nutr Clin Pract 2007; 22: 297-304.
10. Dao CN, Patel P, Overton ET, Rhame F, Pals SL, Johnson C, Bush T, Brooks JT. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011; 52: 396-405.
11. Viard J-P, Souberbielle J-C, Kirk O, Reekie J, Knysz B, Losso M, Gatell J, Pedersen C, Bogner JR, Lundgren JD, Mocroft A. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS 2011; 25: 1305-1315.
12. Kim JH, Gandhi V, Psevdos G, Espinoza F, Park J, Sharp V. Evaluation of Vitamin D Levels among HIV-Infected Patients in New York City. AIDS Research and Human Retroviruses [Internet]. Available at http://www.ncbi.nlm.nih.gov/pubmed/21644847 (last accessed 4 December 2012).
13. Mueller NJ, Fux CA, Ledergerber B, Elzi L, Schmid P, Dang T, Magenta L, Calmy A, Vergopoulos A, Bischoff-Ferrari HA. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS 2010; 24: 1127-1134.
14. Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, Sweep FC, Hermus AR, Bosch ME, Burger DM, Bravenboer B, Koopmans PP, Van Der Ven AJ. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24: 1375-1382.
15. Rodríguez M, Daniels B, Gunawardene S, Robbins GK. High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses 2009; 25: 9-14.
16. Bang UC, Shakar SA, Hitz MF, Jespersen MS, Andersen O, Nielsen SD, Jensen JE. Deficiency of 25-hydroxyvitamin D in male HIV-positive patients: a descriptive cross-sectional study. Scand J Infect Dis 2010; 42: 306-310.
17. Stein EM, Yin MT, McMahon DJ, Shu A, Zhang CA, Ferris DC, Colon I, Dobkin JF, Hammer SM, Shane E. Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women. Osteoporos Int 2011; 22: 477-487.
18. Milazzo L, Mazzali C, Bestetti G, Longhi E, Foschi A, Viola A, Vago T, Galli M, Parravicini C, Antinori S. Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population. Curr HIV Res 2011; 9: 186-193.
19. Vescini F, Cozzi-Lepri A, Borderi M, Re MC, Maggiolo F, De Luca A, Cassola G, Vullo V, Carosi G, Antinori A, Tozzi V, Monforte AD. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. J Acquir Immune Defic Syndr 2011; 58: 163-172.
20. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 2004; 29: 664-673.
21. Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta 2011; 1814: 186-199.
22. Pasquet A, Viget N, Ajana F, de la Tribonniere X, Dubus S, Paccou J, Legroux-Gérot I, Melliez H, Cortet B, Yazdanpanah Y. Vitamin D deficiency in HIV-infected patients: associated with non-nucleoside reverse transcriptase inhibitor or efavirenz use? AIDS 2011; 25: 873-874.
23. Lattuada E, Lanzafame M, Zoppini G, Concia E, Vento S. No influence of nevirapine on vitamin D deficiency in HIV-infected patients. AIDS Res Hum Retroviruses 2009; 25: 849-850.
24. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1, 25-dihydroxyvitamin D. AIDS 2003; 17: 513-520.
25. Conesa-Botella A, Florence E, Lynen L, Colebunders R, Menten J, Moreno-Reyes R. Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. AIDS Res Ther 2010; 7: 40-46.
26. Fox J, Peters B, Prakash M, Arribas J, Hill A, Moecklinghoff C. Improvement in vitamin D deficiency following antiretroviral regime change: results from the MONET trial. AIDS Res Hum Retroviruses 2011; 27: 29-34.
27. Allavena C, Delpierre C, Cuzin L, Rey D, Viget N, Bernard J, Guillot P, Duvivier C, Billaud E, Raffi F. High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs. J Antimicrob Chemother 2012; 67: 2222-2230.
28. Cervero M, Agud JL, García-Lacalle C, Alcázar V, Torres R, Jusdado JJ etal. Prevalence of vitamin D deficiency and its related risk factor in a spanish cohort of adult HIV-infected patients: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2012; 28: 763-771.
29. Kwan CK, Eckhardt B, Baghdadi J, Aberg JA. Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, New York. AIDS Res Hum Retroviruses 2012; 28: 825-832.
30. Childs KE, Fishman SL, Constable C, Gutierrez JA, Wyatt CM, Dieterich DT, Mullen MP, Branch AD. Short communication: inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses 2010; 26: 855-859.
31. Aloia JF, Li-Ng M, Pollack S. Statins and Vitamin D. Am J Cardiol 2007; 100: 1329.
32. Pérez-Castrillón JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G, Dueñas A. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 2007; 99: 903-905.
33. Yavuz B, Ertugrul DT, Cil H, Ata N, Akin KO, Yalcin AA, Kucukazman M, Dal K, Hokkaomeroglu MS, Yavuz BB, Tutal E. Increased levels of 25 hydroxyvitamin D and 1, 25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther 2009; 23: 295-299.
34. Ertugrul DT, Yavuz B, Cil H, Ata N, Akin KO, Kucukazman M, Yalcin AA, Dal K, Yavuz BB, Tutal E. STATIN-D Study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D. Cardiovasc Ther 2010; 29: 146-152.
35. Ware WR. The JUPITER lipid lowering trial and vitamin D: Is there a connection? Dermatoendocrinol. 2010; 2: 50-54.
36. Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal 2005; 49: 1020-1038.
37. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004; 58: 119-133.
38. Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008; 90: 154-166.
39. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011; 13: 143-151.
40. Team R. others. R: A language and environment for statistical computing. R Foundation for Statistical Computing Vienna Austria. 01/19/2010.
41. Mawer EB, Schaefer K, Lumb GA, Stanbury SW. The metabolism of isotopically labelled vitamin D3 in man: the influence of the state of vitamin D nutrition. Clin Sci 1971; 40: 39-53.
42. Vieth R. Vitamin D nutrition and its potential health benefits for bone, cancer and other conditions. J Nutr Environ Med 2001; 11: 275-291.
43. Jones KS, Schoenmakers I, Bluck LJC, Ding S, Prentice A. Plasma appearance and disappearance of an oral dose of 25-hydroxyvitamin D2 in healthy adults. Br J Nutr 2011; 7: 1-10.
44. Ish-Shalom S, Segal E, Salganik T, Raz B, Bromberg IL, Vieth R. Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. J Clin Endocrinol Metab 2008; 93: 3430-3435.
45. Ross AC, Taylor CL, Yaktine AL, Del Valle HB, eds. Dietary Reference Intakes for Calcium and Vitamin D. Washington DC: National Academies Press, 2011.
46. Ilahi M, Armas LAG, Heaney RP. Pharmacokinetics of a single, large dose of cholecalciferol. Am J Clin Nutr 2008; 87: 688-691.